Sarah M. Glass
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sarah M. Glass has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Frederick Peter Guengerich
Department of Biochemistry, Vanderbilt University School of Medicine
5 shared publications - Michael J. Reddish
Department of Chemistry and Fermentation Sciences, Appalachian State University, Boone, North Carolina
3 shared publications - Laura Lowe Furge
Department of Chemistry, Kalamazoo College, Kalamazoo, Michigan
2 shared publications - Alexander S. Burns
Global Discovery Chemistry
1 shared publication Alexandria K. Oswalt
Department of Chemistry, Kalamazoo College, Kalamazoo, Michigan
1 shared publication- Ana G. Vergara
Department of Pharmacokinetics, Dynamics, Metabolism, and Bioanalytics, Merck & Co., Inc
1 shared publication
Latest Publications
- 3 July 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (14) , 14405-14415
Strategies to Improve Pharmacokinetics of Hepatic Uptake Transporter Substrates
For hepatic uptake transporter substrates, hepatic clearance depends not only on the rates of elimination (metabolism and biliary excretion) but also on the rates at which a drug moves between the liver and bloodstream. With representative extended clearance classification system Class 1B drugs, we performed mouse in vivo studies with chemical inhibitors of metabolism and hepatic uptake to demonstrate how permeability affects the relative contributions of hepatic uptake and metabolism to clearance. In addition, we show how half-life can be extended through reductions in metabolism but is largely unaffected by changes in hepatic uptake. Insights from the extended clearance model and pharmacokinetic modeling are used to supplement these studies. While most literature focuses on reducing hepatic uptake as the main strategy to reduce clearance for this class of drugs, we present a rationale to reduce clearance and extend half-life by increasing permeability and reducing metabolism.
- 3 July 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (14) , 14405-14415
Strategies to Improve Pharmacokinetics of Hepatic Uptake Transporter Substrates
For hepatic uptake transporter substrates, hepatic clearance depends not only on the rates of elimination (metabolism and biliary excretion) but also on the rates at which a drug moves between the liver and bloodstream. With representative extended clearance classification system Class 1B drugs, we performed mouse in vivo studies with chemical inhibitors of metabolism and hepatic uptake to demonstrate how permeability affects the relative contributions of hepatic uptake and metabolism to clearance. In addition, we show how half-life can be extended through reductions in metabolism but is largely unaffected by changes in hepatic uptake. Insights from the extended clearance model and pharmacokinetic modeling are used to supplement these studies. While most literature focuses on reducing hepatic uptake as the main strategy to reduce clearance for this class of drugs, we present a rationale to reduce clearance and extend half-life by increasing permeability and reducing metabolism.
- 3 July 2022
- Published by Taylor & Francis in Drug Metabolism Reviews
- Vol. 54 (3) , 318-330
Epigenetics in drug disposition & drug therapy: symposium report of the 24th North American meeting of the International Society for the Study of Xenobiotics (ISSX)
The 24th North American International Society for the Study of Xenobiotics (ISSX) meeting, held virtually from September 13 to 17, 2021, embraced the theme of “Broadening Our Horizons.” This reinforces a key mission of ISSX: striving to share innovative science related to drug discovery and development. Session speakers and the ISSX New Investigator Group, which supports scientific and professional development of student and early career ISSX members, elected to highlight the scientific content presented during the captivating session titled, “Epigenetics in Drug Disposition & Drug Therapy”. The impact genetic variation has on drug response is well established; however, this session underscored the importance of investigating the role of epigenetics in drug disposition and drug discovery. Session speakers, Drs. Ning, McClay, and Lazarus, detailed mechanisms by which epigenetic players including long non-coding RNA (lncRNAs), microRNA (miRNAs), DNA methylation, and histone acetylation can alter the expression of genes involved in pharmacokinetics, pharmacodynamics, and toxicity. Dr. Ning detailed current knowledge about miRNAs and lncRNAs and the mechanisms by which they can affect expression of drug metabolizing enzymes (DMEs) and nuclear receptors. Dr. Lazarus discussed the potential role of miRNAs on UDP-glucuronosyltransferase (UGT) expression and activity. Dr. McClay provided evidence that aging alters methylation and acetylation of DMEs in the liver, affecting gene expression and activity. These topics, compiled by the symposium organizers, presenters, and the ISSX New Investigators Group, are herein discussed, along with exciting future perspectives for epigenetics in drug disposition and drug discovery research.
- 3 July 2022
- Published by Taylor & Francis in Drug Metabolism Reviews
- Vol. 54 (3) , 318-330
Epigenetics in drug disposition & drug therapy: symposium report of the 24th North American meeting of the International Society for the Study of Xenobiotics (ISSX)
The 24th North American International Society for the Study of Xenobiotics (ISSX) meeting, held virtually from September 13 to 17, 2021, embraced the theme of “Broadening Our Horizons.” This reinforces a key mission of ISSX: striving to share innovative science related to drug discovery and development. Session speakers and the ISSX New Investigator Group, which supports scientific and professional development of student and early career ISSX members, elected to highlight the scientific content presented during the captivating session titled, “Epigenetics in Drug Disposition & Drug Therapy”. The impact genetic variation has on drug response is well established; however, this session underscored the importance of investigating the role of epigenetics in drug disposition and drug discovery. Session speakers, Drs. Ning, McClay, and Lazarus, detailed mechanisms by which epigenetic players including long non-coding RNA (lncRNAs), microRNA (miRNAs), DNA methylation, and histone acetylation can alter the expression of genes involved in pharmacokinetics, pharmacodynamics, and toxicity. Dr. Ning detailed current knowledge about miRNAs and lncRNAs and the mechanisms by which they can affect expression of drug metabolizing enzymes (DMEs) and nuclear receptors. Dr. Lazarus discussed the potential role of miRNAs on UDP-glucuronosyltransferase (UGT) expression and activity. Dr. McClay provided evidence that aging alters methylation and acetylation of DMEs in the liver, affecting gene expression and activity. These topics, compiled by the symposium organizers, presenters, and the ISSX New Investigators Group, are herein discussed, along with exciting future perspectives for epigenetics in drug disposition and drug discovery research.
- 31 October 2021
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 714, 109076
Binding of cytochrome P450 27C1, a retinoid desaturase, to its accessory protein adrenodoxin
- 31 October 2021
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 714, 109076
Binding of cytochrome P450 27C1, a retinoid desaturase, to its accessory protein adrenodoxin
- 1 April 2021
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 208, 105787
Characterization of human adrenal cytochrome P450 11B2 products of progesterone and androstenedione oxidation
- 1 April 2021
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 208, 105787
Characterization of human adrenal cytochrome P450 11B2 products of progesterone and androstenedione oxidation
- 1 November 2020
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 694, 108596
Functional interactions of adrenodoxin with several human mitochondrial cytochrome P450 enzymes
- 1 November 2020
- Published by Elsevier in Archives of Biochemistry and Biophysics
- Vol. 694, 108596
Functional interactions of adrenodoxin with several human mitochondrial cytochrome P450 enzymes
- Open Access
- 1 June 2019
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 294 (26) , 10028-10041
Conformational selection dominates binding of steroids to human cytochrome P450 17A1
- 1 June 2019
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 294 (26) , 10028-10041
Open AccessConformational selection dominates binding of steroids to human cytochrome P450 17A1
- 1 June 2019
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 47 (6) , 567-573
Rolapitant Is a Reversible Inhibitor of CYP2D6
Rolapitant [(Varubi), 5S,8S)-8-[[(1R)-1-[3,5 bis(trifluoromethyl phenyl]ethoxy]methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one] is a high-affinity NK1 receptor antagonist that was approved in September 2015 as a treatment for nausea and vomiting caused by chemotherapy. In vivo rolapitant moderately inhibits CYP2D6 for at least 7 days after one 180 mg dose. Due to the long inhibition time, we investigated rolapitant as a possible mechanism-based inactivator of CYP2D6. Rolapitant docked in the active site of CYP2D6 and displayed type I binding to CYP2D6 with a Ks value of 1.2 ± 0.4 µM. However, in NADPH-, time-, and concentration-dependent assays of CYP2D6 activity, no evidence for mechanism-based inactivation and no metabolites of rolapitant were observed. Stopped-flow binding studies yielded a kon/koff (Kd) value of 6.2 µM. The IC50 value for rolapitant inhibition of CYP2D6 activity was 24 µM, suggesting that inhibition is not due to tight binding of rolapitant to CYP2D6. By Lineweaver-Burk analysis, rolapitant behaved as a mixed, reversible inhibitor. The Ki values of 20 and 34 µM were determined by Dixon analysis, with bufuralol and dextromethorphan as reporter substrates, respectively, and drug-drug interaction modeling did not predict the reported in vivo inhibition. The interaction of rolapitant with CYP2D6 was also examined in 1 microsecond molecular dynamics simulations. Rolapitant adopted multiple low-energy binding conformations near the active site, but at distances not consistent with metabolism. Given these findings, we do not see evidence that rolapitant is a mechanism-based inactivator. Moreover, the reversible inhibition of CYP2D6 by rolapitant may not fully account for the moderate inhibition described in vivo.
- 1 June 2019
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 47 (6) , 567-573
Rolapitant Is a Reversible Inhibitor of CYP2D6
Rolapitant [(Varubi), 5S,8S)-8-[[(1R)-1-[3,5 bis(trifluoromethyl phenyl]ethoxy]methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one] is a high-affinity NK1 receptor antagonist that was approved in September 2015 as a treatment for nausea and vomiting caused by chemotherapy. In vivo rolapitant moderately inhibits CYP2D6 for at least 7 days after one 180 mg dose. Due to the long inhibition time, we investigated rolapitant as a possible mechanism-based inactivator of CYP2D6. Rolapitant docked in the active site of CYP2D6 and displayed type I binding to CYP2D6 with a Ks value of 1.2 ± 0.4 µM. However, in NADPH-, time-, and concentration-dependent assays of CYP2D6 activity, no evidence for mechanism-based inactivation and no metabolites of rolapitant were observed. Stopped-flow binding studies yielded a kon/koff (Kd) value of 6.2 µM. The IC50 value for rolapitant inhibition of CYP2D6 activity was 24 µM, suggesting that inhibition is not due to tight binding of rolapitant to CYP2D6. By Lineweaver-Burk analysis, rolapitant behaved as a mixed, reversible inhibitor. The Ki values of 20 and 34 µM were determined by Dixon analysis, with bufuralol and dextromethorphan as reporter substrates, respectively, and drug-drug interaction modeling did not predict the reported in vivo inhibition. The interaction of rolapitant with CYP2D6 was also examined in 1 microsecond molecular dynamics simulations. Rolapitant adopted multiple low-energy binding conformations near the active site, but at distances not consistent with metabolism. Given these findings, we do not see evidence that rolapitant is a mechanism-based inactivator. Moreover, the reversible inhibition of CYP2D6 by rolapitant may not fully account for the moderate inhibition described in vivo.
- Open Access
- 1 April 2019
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 294 (16) , 6522-6530
Isotopic tagging of oxidized and reduced cysteines (iTORC) for detecting and quantifying sulfenic acids, disulfides, and free thiols in cells
- 1 April 2019
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 294 (16) , 6522-6530
Open AccessIsotopic tagging of oxidized and reduced cysteines (iTORC) for detecting and quantifying sulfenic acids, disulfides, and free thiols in cells